Company / R&D per Share
OCULAR THERAPEUTIX, INC R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$1.25
FY2025
5-year range
$0.37 / $1.25
FY2021-FY2025
Trend
+12.5%
vs FY2024
Sector context
#138 of 208
Health Care
What the data says
At $1.25, OCULAR THERAPEUTIX, INC's r&d per share ranks #138 of 208 in the Health Care sector. R&D per Share has increased for 3 consecutive years, from $0.37 in FY2022 to $1.25 in FY2025.
Based on SEC 10-K filings.
1.25 in FY2025 with a 5-year CAGR of +8.9%.
Improved from $0.79 to $1.25 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +49.5%
- 5-Year CAGR
- +8.9%
- 10-Year CAGR
- -
Sector benchmark
#138 of 208 in Health CareTop 66% of 208This company $1.25 Sector average $12.19
▼
-89.8% below sector average
Key checks
Key Insights
- OCULAR THERAPEUTIX, INC's r&d per share has grown for 3 consecutive years.
- In FY2025, r&d per share increased 12.5% year-over-year.
- Ranks #138 out of 208 companies in the Health Care sector.
- Lowest r&d per share in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score 0.25 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.25 | +12.5% |
| FY2024 | $1.11 | +40.4% |
| FY2023 | $0.79 | +111.5% |
| FY2022 | $0.37 | -30.8% |
| FY2021 | $0.54 | -33.8% |
| FY2020 | $0.82 | +9.8% |
| FY2019 | $0.74 | -40.2% |
| FY2018 | $1.24 | +0.9% |
| FY2017 | $1.23 | +12.8% |
| FY2016 | $1.09 | +121.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026